Navigation Links
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Date:10/23/2007

Company on Target to File Second New Drug Application for TREANDA by End of

2007

FRAZER, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a Phase 3 clinical trial of TREANDA(R) (bendamustine HCl) in patients with indolent non-Hodgkin's lymphoma (NHL) whose cancer is no longer responsive to treatment with rituximab. The study met its primary endpoints of overall response rate and median duration of response, while demonstrating a manageable tolerability profile. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

The Phase 3, multicenter, single-arm study evaluated the efficacy and safety of single-agent TREANDA in 100 patients with relapsed, rituximab-refractory NHL. The overall response rate, as assessed by an independent radiological committee, was 75% (p<0.0001) and the median duration of response was 40 weeks (or 9.2 months). The overall response rate includes the percent of patients in the trial who had a complete, unconfirmed complete or partial response to treatment. The most common side effects included nausea, fatigue, neutropenia, diarrhea and vomiting. The company anticipates that the results of this study will be released at the upcoming American Society of Hematology (ASH) annual meeting in December 2007.

"We are encouraged that these results replicate those seen in our Phase 2 study, confirming the substantial efficacy in this difficult to treat population," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on these positive results, we are on track to file a New Drug Application in the fourth quarter for TREANDA in patients with indolent NHL who have failed treat
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)...  A central New York ... Total Artificial Heart implant is home, discharged from ... Freedom® portable driver to wait for a matching ... from a Syracuse architectural hardware company, suffered from ... medications, an implantable defibrillator and a pacemaker. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... RIDGEFIELD, Conn., Oct. 24, 2011 Apelon, ... data interoperability solutions, today announced the availability ... solution. TermManager, a code set management and ... interoperability initiatives by enabling widespread access to ...
... Codexis, Inc. (Nasdaq: CDXS ) ... Codex® Screening Kits are in use or evaluation ... worldwide.  The announcement was made at CPhI  Worldwide, ... week.   Codex® Screening Kits were ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/22/2014)... 2014 As reported on July 17, 2014 ... to name her favorite beauty products, “ Botox , that’s ... that “ Botox has changed my life” by halving ... preparing for her various, daily appearances. “Suddenly my eyelids ... (see: goo.gl/shmTQM). , “I think that Kelly Ripa’s response to ...
(Date:7/22/2014)... certain pathogenic mechanisms with cancer, according to a new ... Kusner, Ph.D. , published in PLOS ONE ... that the very same inhibitors of apoptosis, or cell ... produce autoimmune diseases. Henry Kaminski, M.D. , chair ... of Medicine and Health Sciences (SMHS), as well as ...
(Date:7/22/2014)... (LALCA 2014) will be held August 21 23, ... the leading cause of death not only in Latin ... previous conferences in Chile, Mexico, Argentina and Brazil, international ... in the treatment and prevention of lung cancer and ... With tobacco being the leading cause of morbi-mortality worldwide ...
(Date:7/22/2014)... Ticket Down is a reliable source for ... in Landover, MD. There has never been a better time ... After the success of the American national soccer team at the ... One way that fans of the world’s sport will be able ... Guinness International Champions Cup. The tournament will kick off on July ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... the way in providing resources, educational tools and recognition ... tell the stories of prevention, treatment and recovery. On ... BLACK BOX will spotlight some of these resources with ... Health Services Administration helpline and treatment website at the ...
Breaking Medicine News(10 mins):Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2
... concerned, the Indian State of Kerala leads the rest of the ... ahead where life expectancy, infant mortality and birth rate are concerned. ... people, while it is at 24.80 for the entire nation. Likewise, ... of the country and infant mortality is at 11, far lower ...
... Reports of increased incidence of kidney failure following use ... necessity for reconsidering the use of the drug in ... to prevent excessive bleeding in patients undergoing cardiac surgery. ... present study that Trasylol injected patients were twice as ...
... virus scare is too much to handle, Hepatitis C alone ... is to the liver which leads to both acute and ... any anti viral therapy to be produced against it the ... few hours or days. This has been a major problem ...
... The bird flu’s virulent H5N1 strain has been discovered in ... Health (OIE). This has given rise to fears that a ... fist incidence of bird flu in the Continent. Preventive measures ... Nigerian authorities, with regard to animals and birds. ...
... Food and Drug Administration has found that newer medicines could ... makers and apprised them of their concerns regarding that particular// ... testing. ,The report by consulting firm Booz Allen ... of drug makers who met with the FDA before conducting ...
... doctors have been pampered by provision of gifts, tickets ... as a part of the promotional campaign. In addition, ... ,What do they expect in favor? Nothing more ... an attempt to prevent such unethical exchanges, certain formulations ...
Cached Medicine News:Health News:Safety Of Heart Drug Questioned 2Health News:Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure! 2Health News:Drug Makers Banned From Providing Gifts To Doctors 2
... DNA Engine instrument is the cycler ... Unprecedented thermal uniformity and swappable blocks ... This rugged machine is ... a platform for new features and ...
MBS 0.5 ml satellite block unit with height adjusting heated lid, 96 standard well block - holds up to 48 x 0.5ml tubes or 96 x 0.3ml tubes, includes tube thermistor)...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
... kit. Includes configured PC with PCR authorized ... satellite thermal Cycler (non-robotic). System expandable ... Store/track run data. Gradient capability. ... uniformity. Advanced control algorithms for reduced ...
Medicine Products: